JPRN-UMIN000002783已完成未知
A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutations - A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutations
agano lung cancer study meeting0 个研究点目标入组 15 人开始时间: 2009年11月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)interstitial pneumonia on computed tomography scan 2)liver cirrhosis, uncontrolled diabetes mellitus, cardiac infarciton and cereral apoplexy onset within three months 3)othere active cancer 4)symptomatic brain metastases 5)need to plan the radiotherapy included in the lung field 6)history of sever drug allegy 7)judged to be inappropriate by the attending doctor
研究者
相似试验
已完成
2 期
phase II study of gefitinib as a first-line therapy in elderly patients with lung adenocarcinoma.JPRN-C000000136West Japan Oncology Group30
已完成
2 期
A Phase II study of Gefitinib as First-Line Treatment for Elderly Patients with Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.on-Small-Cell Lung CancerJPRN-UMIN000001863Central Japan Lung Study Group19
已完成
2 期
A phase II study of first-line gefitinib for advanced and recurrent EGFR mutation positivenon-small cell lung cancerwith high-risk factorsnon-small cell lung cancerJPRN-UMIN000004822Kanagawa Cancer Center37
招募中
1 期
A Phase I/II trial to evaluate gefitinib and concurrent postoperative chemoradiation in patients with advanced resectable head and neck cancerACTRN12605000510640peter maccallum Cancer Centre70
已完成
2 期
Phase II trial of induction gefitinib followed by cisplatin and docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer with EGFR activating mutationon-small cell lung cancerJPRN-UMIN000005086ung Oncology Group in Kyushu, Japan (LOGIK)21